A RETROSPECTIVE ASSESMENT OF CLINICAL OUTCOMES ASSOCIATED WITH MULTI – DRUG REGIMEN APPROACHES IN PATIENTS WITH DIABETES MELLITUS

Devika. S*[1] , Vijayasarathi. J*[2] , Mohitha Sree K.K[3] , Sethu. M [4] , Ramsaran. K.S[5] , Sabariananthan. D[6] , Manoj kumar .P*[7] Surendra Kumar. M[8]

*1 , *7 -Assistant Professor, Department of pharmacy practice, Senghundhar collage of Pharmacy, Tiruchengode, 637 205, Namakkal Dt, Tamil Nadu.

2*-6 - Student, Department of pharmacy practice, Senghundhar collage of Pharmacy, Tiruchengode, 637 205, Namakkal Dt, Tamil Nadu.

8- Principal, Department of pharmacy practice, Senghundhar collage of Pharmacy, Tiruchengode, 637 205, Namakkal Dt, Tamil Nadu.

Corresponding Author: Devika.S

Vijayasarathi.j

ABSTRACT

Diabetes mellitus is a chronic metabolic disorder requiring long-term pharmacological management to achieve optimal glycemic control and prevent complications. The present retrospective study aimed to assess the clinical outcomes associated with multi-drug regimen approaches in patients diagnosed with diabetes mellitus. Medical records of patients receiving combination pharmacotherapy over a defined period were reviewed to evaluate glycemic parameters, incidence of diabetes-related complications, hospitalization rates and medication adherence. The findings indicated that patients treated with multi-drug regimens demonstrated significant improvement in glycemic control, evidenced by reductions in fasting blood glucose and glycated haemoglobin (HbA1c) levels.However, increased pill burden and the potential risk of adverse drug reactions were noted in a subset of patients. Overall, the study highlights the clinical effectiveness of multi-drug regimen strategies in optimizing therapeutic outcomes among diabetic patients, while emphasizing the importance of individualized treatment planning, regular monitoring, and patient education to minimize complications and enhance adherence. Further prospective studies are recommended to validate these findings and establish standardized treatment protocols.

KEYWORDS

Multi-drug regimen, Combination pharmacotherapy, Glycemic control, HbA1c, Clinical outcomes, Retrospective study.

INTRODUCTION

Diabetes is a complex, chronic condition that requires constant medical care as well as a variety of risk-reduction strategies, beyond blood sugar regulation. Ongoing diabetes self management education and support are critical to empowering individuals, preventing acute complications, and reducing the risk of long-term repercussions. Numerous interventions targeted at improving diabetes outcomes have strong evidence to support them. (El Sayed., et al., 2022).

Conventional diabetes detection techniques, which frequently depend on fasting blood glucose levels or HbA1c readings, have drawbacks, such as the possibility of a delayed diagnosis as well as the necessity of therapeutic visits Many patients have limited access to standard healthcare services, especially those who live in underserved or distant areas, which causes delays in diagnosis and treatment. (Abousaber., et al., 2025).

Primary care physicians, endocrinologists, nurse practitioners, physician associates/assistants, pharmacists, nutritionists, and diabetes care and education experts are among the intended audience for the Standards of Care. Specialists including cardiologists, nephrologists, emergency physicians, internists, paediatricians, psychiatrists, neurologists, ophthalmologists, and podiatrists who treat patients with diabetes and its many consequences can also find assistance in the Standards of Care. (Care., et al., 2023).

Dietary regimens and physical exercise are modifiable risk factors for diabetes. Reddy therefore suggested low-sugar diets that could either prevent or postpone the onset of diabetes. Reddy also discovered that regular blood pressure and cholesterol levels may lessen the onset of diabetes and the symptoms of prediabetes Researchers found that women with gestational diabetes who used rtCGM as opposed to SMBG had considerably better overall glycemic control, lower glycemic variability, and lower mean child birth weight. (Phillip., et al., 2021).

The purpose of the American Diabetes Association's (ADA) "Standards of Medical Care in Diabetes," also known as the Standards of Care, is to give clinicians, researchers, policy makers, and other interested parties the components of diabetes care, general treatment goals, and instruments to assess the quality of care. The American Diabetes Association works to update and enhance the Standards of Care so that policy makers, health plans, and physicians can continue to rely on it as the most reliable source for up-to-date diabetes care standards. (American Diabetes Association., et al., 2022).

Studies have demonstrated strong correlations between diabetic kidney disease and the other diabetes microvascular sequelae of retinopathy and neuropathy, in addition to the correlations between diabetic kidney disease and mortality and the macrovascular complication of cardiovascular disease, critical importance to the health of the patient. Often, as kidney disease worsens, the nephrologist becomes the main care provider that the patient routinely sees. (Stanton., et al., 2014).

The possibility of SGLT2i-mediated euglycemic ketoacidosis in people without diabetes, even with sufficient insulin secretory capacity, is confirmed by these two instances. The finding that SGLT2i-associated ketoacidosis can occur in people without diabetes has important ramifications for how these patients are managed in high-risk ketogenic settings. (Umapathysivam., et al., 2024). (Ibrahim., et al., 2023).

The top ten countries in the world with the highest rates of diabetes are India, China, the United States, Indonesia, Japan, Pakistan, Russia, Brazil, Italy and Bangladesh. As a result, this health issue has become a global emergency. Due to the possibility of serious COVID-19-related illnesses, glycemic management has been the subject of substantial research. (Hossain., et al., 2024).

Low-income individuals put off receiving a diabetes diagnosis until maturity due to financial limitations, which can lead to major health problems. Germany has diabetes rates of 8.2% and 9.0%, while Egypt and Mexico had rates of 16.8% and 12.6%, respectively, as well as the US. (Sepanlou et al., 2017). According to a new study, diabetes is starting to affect people all around the world. Globally, diabetes is becoming more and more expensive, particularly in low-income nations. (Rafiq., et al., 2024).

High blood sugar levels brought on by either insufficient insulin synthesis or resistance to insulin action are another feature of diabetes, a chronic metabolic disorder. Numerous consequences, such as neuropathy, retinopathy, kidney disease and cardiovascular disease, are linked to diabetes. To examine diabetic patients' risk factors and discuss the advancements and potential applications of machine learning in the field of illness diagnosis. (Wang 2024 et al.,)

Chronic hyper-glycemia is the hallmark of the condition, which is defined by poor glucose metabolism brought on by insulin resistance or insufficiency. In addition to causing physical issues like neuropathy, nephropathy and cardiovascular disease, diabetes mellitus has a substantial effect on the patients general quality of life, including social and psychological elements. (Asmi., et al., 2024).

Conventional diabetes detection techniques, which frequently depend on fasting blood glucose levels or HbA1c readings, have drawbacks, such as the possibility of a delayed diagnosis. Regarding the necessity of clinical visits. (Abousaber et al., 2025). In order to map pertinent peer-reviewed literature and determine the current state of practice in the field of PHM for individuals with type 2 diabetes, a scoping review was conducted. PHM is a promising strategy for improving long-term health in populations with chronic illnesses. It may stabilize and even lower overall expenditures, supporting the sustainability of healthcare systems. (Geurten., et al., 2024).

In clinical practice, regularly used medications may decrease glycaemic management in people with diabetes or interfere with glucose homeostasis, causing impaired glucose tolerance, hyper-glycemia or new-onset diabetes mellitus. GCs are most frequently linked to the onset of acute hyper-glycemia or diabetes and GC-induced diabetes mellitus (GCIDM) has been recognized for more than 60 years. (Scheen., et al., 2022).

Insulin is one of the primary and essential exogenous medications used to treat diabetes, regardless of the absolute or relative lack of insulin secretion in patients with T1DM and severe T_2DM. (Zhao., et al., 2020). There is mounting evidence that T_2DM has a role in the development and progression of HCC. Anti-DM medications have been linked to the development of HCC, according to studies. We go over how anti-DM medications affect HCC in this section. outlines how anti-DM medications affect the development and occurrence of HCC. (Mai., et al., 2024).

Pharmaceutical medications can have a number of detrimental side effects when taken over an extended period of time. They may be suggested as dietary supplements to stop or lessen T_2DM-related problems. In addition to the pre-diabetic and early stages of type 2 diabetes, the advanced stages of the disease may also benefit from the usage of natural medicines. (Blahova., et al., 2021).

For a long time, type 2 diabetes mellitus (T_2DM) was known as non-insulin dependent diabetes or adult-onset diabetes with insulin resistance that could eventually increase to absolute resistance. Studies on children showed that obesity, insulin resistance and cell dysfunction coexist, much as they do in older T_2DM patients. (Artasensi., et al., 2021).

Researchers using various classification techniques have carried out a number of studies on DRPs. According to a 2018 study conducted in Tegal, Indonesia, the biggest DRPs of all incidents were drug dose and drug choice issues. (Hartuti., et al., 2021).

REVIEW OF LITERATURE

(Bo, Y. et al., 2025) The number of persons with diabetes has increased dramatically over the past 35 years, making it a serious worldwide health concern. The International Diabetes Federation (IDF) estimates that 425 million persons worldwide have diabetes, and by 2045, that figure is predicted to increase to 629 million.

(Bhanushali, P. et al., 2024) The impact of diabetes on the prognosis and course of COVID-19, both during the active and recovery stages, as well as the effectiveness of physical treatment for these patients. A sizable section of the populace, including both healthy and immunocompromised people, has been impacted by COVID-19.

(Koshizaka, M. et al., 2024) It is estimated that there is no difference in the incidence of COVID-19 infection between patients with diabetes and those without, with 16% of COVID-19 patients in Japan having diabetes, which is nearly equal to the prevalence of diabetes in the general population. However, compared to individuals without diabetes, COVID-19 patients with diabetes had a two-fold higher risk of developing severe COVID-19 illness and dying.

(Musat, M. et al., 2024) A vital component of the human body, glucose serves as the primary energy source for living cells and is continuously supplied by the bloodstream. Cellular uptake of glucose is necessary for growth, metabolism, and homeostasis. Due to its high molecular mass and polar nature, glucose cannot simply diffuse through the lipid cell membrane. It needs a carrier-mediated process, occurring by passive and active transport processes.

(Petrelli, F. et al., 2024) The prevention, treatment, and research of major chronic diseases linked to modifiable environmental factors like poor diet, physical inactivity, stress, excessive alcohol consumption, and smoking are the main focus of lifestyle medicine (LM), a scientific field with a multidisciplinary approach. 425 million individuals worldwide suffer from diabetes (IDF 2021; age range: 20–79; T2D range: 87–91%).

(Francia, P. et al., 2024) Artificial intelligence (AI) and other new technologies present tremendous potential for improving blood glucose level (BGL) estimate systems, which could improve diabetic patients' care and quality of life. The databases Scopus, Web of Science, Embase, PubMed, and CINAHL were all thoroughly searched.

NEED OF THE STUDY

Diabetes mellitus represents a significant public health burden due to its chronic nature, increasing prevalence, and association with serious microvascular and macrovascular complications such as neuropathy, nephropathy, retinopathy, cardiovascular disease, and stroke. The cornerstone of managing diabetes is effective glycaemic control; nevertheless, in ordinary clinical practice, attaining and maintaining optimal control is still difficult. Many patients are unable to achieve target glycaemic levels with monotherapy alone as the disease advances, which calls for the use of multi-drug regimen approaches that combine insulin therapies and/or oral antidiabetic medicines with complementary modes of action.

Clinical guidelines frequently advocate multi-drug regimens, although their safety and efficacy profiles in the real world may be different from those in controlled clinical trials. Treatment adherence and overall clinical outcomes may be adversely affected by combination therapy patients' complicated dosage schedules, greater pill burden, and increased risk of adverse medication reactions and drug-drug interactions.

Furthermore, especially in settings with limited resources, improper multi-drug regimen selection or escalation may result in hypoglycemia, weight gain, therapeutic duplication, and higher healthcare expenses. A retrospective evaluation of clinical outcomes related to multi-drug regimen techniques provide important information about real prescribing patterns, tolerability in a variety of patient demographics, complication rates, and glycaemic control outcomes.

Such an assessment reveals discrepancies between guidelines and actual practice and aids in determining the advantages and disadvantages of frequently used medication combinations. Additionally, sensible drug use and tailored therapy can be supported by knowledge of patient specific factors impacting treatment response. In order to produce evidence regarding the clinical efficacy, safety, and outcome measures of multi-drug regimens in patients with diabetes mellitus, this study is essential.

Through evidence-based and patient-centered management approaches, the results will help healthcare professionals optimize treatment regimens, reduce therapy-related risks, improve patient adherence, and ultimately improve the quality of diabetes care.

AIM AND OBJECTIVES

Aim:

To assess the impact of multi-drug therapy on glycaemic control and diabetes-related outcomes in patients with diabetes mellitus using retrospective patient data.

Objectives:

❖ To evaluate the prescribing patterns of multi-drug regimens used in the management of diabetes mellitus.

❖ To assess the effectiveness of multi-drug therapy in achieving glycaemic control by analyzing clinical parameters such as fasting blood glucose, postprandial blood glucose, and HbA1c levels.

❖ To identify the prevalence of diabetes-related complications in patients receiving multi drug regimens.

❖ To analyse patient adherence and treatment persistence associated with multi-drug regimen approaches.

❖ To assess the impact of multi-drug regimens on overall clinical outcomes and quality of diabetes management.d

❖ To identify factors influencing treatment outcomes, including patient demographics, comorbidities, and duration of diabetes.

METHODOLOGY

STUDY TYPE

This case study is a Retrospective observational study conducted in a Diabetic health care hospital, analysing patient data to assess the clinical outcomes associated with multi-drug regimen approaches in patients with diabetic mellitus

STUDY DESIGN

The study was designed as a Retrospective observational study

STUDY SITE

The study was conducted at the Diabetic outpatient department of MONIKA Diabetes centre, Kalli Appar Street, Railway colony, Nadarmedu, Erode District, Tamil Nadu, India

STUDY DURATION

This study was conducted during the November to December month in 2025

STUDY POPULATION

Patients Diagnosed with Diabetic mellitus and treated with multi-drug antidiabetic therapy and also known Chronic metabolic disease

SAMPLE SIZE

Considered The Diabetic studies among the general population in India as 2% with a margin of error is 5% and 95% confidence interval, the sample size was calculated as

$$n = \frac{(Z^2 \times p \times q)}{(d^2)}$$

n = required sample size

Z= standard normal deviate at 95% confidence level (1.96)

p = estimated proportion of diabetic patients receiving multi-drug therapy

q = 1-p d= allowable error (5% or 0.005)

PATIENT SELECTION

Inclusion criteria

- ➢ Patients diagnosed with type 1 or type 2 diabetes mellitus
- ➢ Patients receiving two or more antidiabetic medications
- ➢ Patients with complete medical records
- ➢ Adult patients (≥18 years)

Exclusion Criteria

- ➢ Patients on monotherapy
- ➢ Patients with incomplete or missing clinical data
- ➢ Pregnant women with gestational diabetes
- ➢ Patients with severe comorbid conditions affecting outcome assessment

SOURCE OF DATA

- ➢ Patient case file
- ➢ Direct interview with patients and caretakers
- ➢ Hospital billing data

OUTCOME MEASURES

Primary outcomes:

Glycaemic control assessed using FBS, PPBS, and HbA1c levels

Secondary outcomes:

Incidence of hypoglycaemia, adverse drug reactions, diabetes-related complications, and treatment adherence

Expected Outcome

The study is expected to provide real-world evidence on the effectiveness and safety of multi drug regimen approaches and support optimization of diabetes management strategies.

RESULT

GENDER WISE DISTRIBUTION OF PATIENTS:

From the total of 150 patients included in the study, 101 patients (67%) were male and 49 patients (33%) were female. This indicates that the majority of the study population were males compared to females.



Gender wise distribution of patients

SOCIAL BEHAVIOUR CATEGORIZATION OF PATIENTS

Out of the total 150 patients included in the study, 95 patients (64%) were non-alcoholic and non-smokers. A total of 25 patients (17%) were alcoholic, 14 patients (9%) were smokers and 16 patients (10%) reported both alcohol consumption and smoking. This indicates that the majority of the study population did not have alcohol or smoking habits.



Social behavior categorization of patients

BODY MASS INDEX CATEGORY OF THE PATIENTS

Out of the total 150 patients included in the study, 8 patients (5%) were underweight (BMI <18.5). A majority of 67 patients (44%) had a healthy weight (BMI 18.5–24.9). Additionally, 57 patients (38%) were overweight (BMI 25.0–29.9) and 20 patients (13%) were obese (BMI ≥30).

Among the obese patients, 1 patient (1%) belonged to Class I obesity, 1 patient (1%) to Class II obesity and 18 patients (11%) to Class III obesity. This shows that most patients were either in the healthy weight or overweight category





Body mass index category of the patients

FAMILY HISTORY OF DIABETIC PATIENTS

Out of the total 150 diabetic patients included in the study, 70 patients (47%) had a positive family history of diabetes, whereas 80 patients (53%) did not have any family history of diabetes. This indicates that a slightly higher proportion of patients did not report a family history of diabetes compared to those who did.



	NO . OF . PATIENTS (150)	PERCENTAGE
NO	80	53%
YES	70	47%

Family history of diabetic patients

GLYCATED HEMOGLOBIN (HBA1C) CATEGORY OF DIABETIC PATIENTS

Out of 150 patients, 146 (98%) had HbA1c levels in the diabetic range (>6.5%). Only 2 patients (1%) had normal HbA1c levels (<5.7%) and 2 patients (1%) were in the prediabetic range (5.7–6.4%). The overall mean of HbA1c was reported as 50.0, with the standard deviation of 83.14.



Glycated hemoglobin category of diabetic patients

FASTING BLOOD SUGAR (FBS) + POSTPRANDIAL BLOOD SUGAR (PPBS) OF PATIENTS

Among the 150 patients, based on PPBS values, 112 patients (75%) were normal, 30 patients (20%) were pre-diabetic and 8 patients (5%) had diabetes mellitus. Based on FBS values, 128 patients (86%) were normal, 14 patients (9%) were pre-diabetic and 8 patients (5%) had diabetes mellitus. The mean for PPBS was reported as 50, with the standard deviation of 44.75, and for FBS it was 50 ± 55.2.



FBS+PPBS of patients

PRESENT MEDICATION OF DIABETIC PATIENTS:

I. MONOTHERAPY OF DIABETIC PATIENTS

Out of the total 150 diabetic patients included in the study, monotherapy was prescribed to a proportion of patients. Among them, 20% of patients received DPP4 inhibitors, 30% were treated with sulfonylureas, 35% received insulin (hormones), and 15% were prescribed biguanides. The mean number of patients receiving monotherapy was reported as 10, with the standard deviation of 1.83. Statistical analysis showed a p-value of 0.80, indicating that there was no statistically significant difference among the various monotherapy drug groups ($p > 0.05$).



Monotherapy of diabetic patients

II. DUALTHERAPY OF DIABETIC PATIENTS:

Out of 150 diabetic patients on dual therapy, the most commonly prescribed combination was Biguanides + Sulfonylurea, accounting for 50% (75 patients). This was followed by Hormones, Biguanides + Sulfonylurea, which constituted 15% (23 patients). DPP-4 inhibitors + Biguanides were used in 11% (17 patients), while Hormones + Biguanides were prescribed in 9% (14 patients). SGLT2 inhibitors + DPP-4 inhibitors accounted for 10% (15 patients), and SGLT2 inhibitors + Biguanides were the least used combination at 5% (8 patients). The overall mean ± standard deviation was reported as 10.83, with the standard deviation of 4.54, with a p-value of 0.09, indicating no statistically significant difference among the dual therapy combinations.



Dual therapy of diabetic patients

III. POLYTHERAPY OF DIABETIC PATIENTS

Out of the total 150 diabetic patients, 45 patients were on polytherapy. Among them, 26 patients (65%) were treated with Hormones, Biguanides, Sulfonylurea and SGLT2 inhibitors, while 19 patients (45%) received Hormones, Biguanides, Sulfonylurea and DPP-4 inhibitors. The mean ± standard deviation was reported as 22.5, with the standard deviation of 4.95, and the p-value was 0.039, indicating a statistically significant difference between the two polytherapy combinations.



Polytherapy of diabetic patients

SCREENING METHOD FOR DIABETIC PATIENTS

From the screening method data of 150 patients, 138 patients (30%) were screened using HbA1c, 144 patients (40%) were screened using FBS and PPBS, and 138 patients (30%) were screened using RBS. This shows that FBS and PPBS was the most commonly used screening method among the patients.



Screening method for diabetic patients

DISCUSSION

The findings of this retrospective assessment contribute meaningfully to the expanding body of literature evaluating multi-drug therapeutic strategies in diabetes mellitus management. Diabetes is a multifactorial metabolic disorder characterized by progressive deterioration in glycemic control. The complexity of its pathophysiology necessitates interventions that target multiple metabolic pathways. In this context, the observed superiority of combination therapy over monotherapy aligns with established theoretical and clinical frameworks.

The improved glycemic outcomes observed in patients treated with multi-drug regimens likely reflect the synergistic mechanisms of action among different pharmacological classes. For instance, metformin primarily reduces hepatic glucose production, while sulfonylureas stimulate pancreatic insulin secretion. SGLT2 inhibitors enhance urinary glucose excretion, and GLP-1 receptor agonists improve insulin secretion while suppressing glucagon release and promoting satiety. By addressing distinct but complementary mechanisms, combination therapy can achieve a more comprehensive metabolic effect. The retrospective data suggest that patients receiving such combinations achieved more consistent HbA1c reductions compared to those maintained on single agents.

Another important aspect concerns disease progression. Type 2 diabetes is inherently progressive due to ongoing beta-cell dysfunction. Monotherapy often becomes insufficient over time. The results of this assessment demonstrate that timely intensification with additional agents contributes to sustained glycemic control. This finding supports clinical guidelines advocating early combination therapy in patients with markedly elevated baseline HbA1c levels.

The cardiovascular implications of diabetes management warrant special attention. Cardiovascular disease remains the leading cause of morbidity and mortality among individuals with diabetes. The retrospective analysis suggests that regimens incorporating cardioprotective agents, particularly SGLT2 inhibitors and GLP-1 receptor agonists, were associated with reduced cardiovascular events. These findings are consistent with large randomized controlled trials such as EMPA-REG OUTCOME and LEADER, which demonstrated significant cardiovascular benefits with these drug classes. While retrospective data cannot establish causality, the observed associations reinforce current recommendations favoring these agents in high-risk populations.

Renal outcomes also emerged as an important consideration. Diabetic nephropathy is a common complication leading to chronic kidney disease. The analysis suggests slower progression of renal impairment among patients on combination regimens that included Reno protective agents. This observation aligns with evidence indicating that improved glycemic control and specific pharmacological mechanisms contribute to renal preservation.

Despite these benefits, safety considerations must be addressed. Hypoglycemia remains a major concern, particularly with regimens involving insulin or sulfonylureas. Retrospective data indicate higher hypoglycemic incidence in certain combinations, highlighting the need for careful dose titration and patient monitoring. Additionally, gastrointestinal side effects and weight gain were observed in some patients. These findings underscore the importance of balancing efficacy with tolerability.

Adherence challenges represent another critical issue. Multi-drug regimens inherently increase pill burden and complexity, potentially reducing compliance. Retrospective patterns suggest that patients prescribed fixed-dose combinations or once-daily regimens demonstrated better adherence rates. Behavioral and socioeconomic factors likely also influenced compliance. Therefore, therapeutic success depends not only on pharmacological efficacy but also on patient-centered care models incorporating education and support.

The retrospective design of the study introduces certain limitations. Selection bias, incomplete documentation, and lack of randomization may influence findings. Confounding variables such as lifestyle modifications, dietary changes, and physical activity were not consistently recorded, limiting the ability to isolate pharmacological effects. Additionally, variations in follow-up duration may affect outcome comparability. Nevertheless, retrospective assessments provide valuable real-world evidence reflecting clinical practice outside controlled trial settings.

From a broader perspective, the findings emphasize the importance of individualized medicine. The heterogeneity of diabetes requires tailored therapeutic strategies rather than uniform treatment protocols. Factors such as age, comorbid conditions, socioeconomic status, and risk of hypoglycemia must inform regimen selection. Emerging precision medicine approaches may further refine therapeutic decision-making.

LIMITATION OF THE STUDY

❖ As a retrospective assessment, the study relied on previously recorded medical data, which may be incomplete, inaccurate, or inconsistently documented. This limits the ability to establish a clear cause–effect relationship between multi-drug regimens and clinical outcomes.

❖ Factors such as patient lifestyle, dietary habits, physical activity, medication adherence, and socioeconomic status could not be fully controlled, which may have influenced glycemic outcomes.

❖ The study population was limited to patients whose records were available, which may not represent the broader diabetic population. This reduces the generalizability of the findings.

❖ Differences in drug combinations, dosages, duration of therapy, and treatment protocols among patients may have affected the consistency and comparability of outcomes.

❖ Adverse drug reactions and side effects may have been underreported or not fully documented in patient records.

❖ The duration of observation may not have been sufficient to assess long-term outcomes such as cardiovascular events, renal complications, or mortality.

❖ Medication adherence could not be accurately measured, and non-compliance may have influenced treatment effectiveness.

❖ If conducted in a single hospital or institution, the results may not reflect outcomes in different healthcare settings or populations.

CONCLUSION

This retrospective assessment highlights the clinical effectiveness of multi-drug regimens in managing diabetes mellitus. Combination pharmacotherapy demonstrated superior glycemic control compared to monotherapy, with significant reductions in fasting plasma glucose and HbA1c levels. By targeting multiple pathophysiological defects such as insulin resistance, impaired insulin secretion, and increased hepatic glucose output, combination therapy provided better metabolic stabilization, especially in patients with long-standing or poorly controlled diabetes. Individualized treatment was essential, as outcomes varied based on patient factors including age, comorbidities, renal function, and baseline glycemic status.

While multi-drug regimens improved glycemic outcomes, some combinations increased risks of hypoglycemia and gastrointestinal effects. However, newer agents like SGLT2 inhibitors and GLP-1 receptor agonists offered additional cardiovascular and renal benefits. Sustained glycemic control was associated with reduced progression of microvascular and macrovascular complications. Overall, appropriately tailored combination therapy enhances clinical outcomes, though adherence, safety, and patient-specific considerations remain crucial for optimal long-term diabetes management.

FUTURE ASPECTS

❖ Future research should prioritize prospective, longitudinal studies to validate and expand upon the findings observed in retrospective analyses. Randomized controlled trials comparing specific multi-drug combinations in diverse populations would provide stronger causal evidence and clarify optimal sequencing strategies.

❖ The integration of personalized medicine approaches represents a promising avenue. Advances in genomics, metabolomics, and pharmacogenomics may enable clinicians to predict individual responses to specific drug combinations. Biomarker-guided therapy could enhance efficacy while minimizing adverse effects.

❖ Digital health technologies also offer transformative potential. Continuous glucose monitoring systems, mobile health applications, and telemedicine platforms may improve adherence, enable real-time dose adjustments, and enhance patient engagement. Combining pharmacological intensification with technological support may further optimize outcomes.

❖ Additionally, future investigations should explore long-term cardiovascular and renal endpoints associated with emerging drug combinations. Comparative effectiveness research in real-world settings will be crucial to determining cost-benefit balances across healthcare systems.

❖ Finally, patient-centered research examining quality of life, treatment satisfaction, and psychosocial outcomes will enhance understanding of the broader impact of multi-drug regimens. As diabetes management evolves, holistic approaches integrating pharmacological innovation, behavioral support, and technological advancement will shape the next generation of therapeutic strategies.

❖ Prospective longitudinal studies, Personalized medicine approaches using pharmacogenomics, Long-term cardiovascular and renal outcome evaluation, Cost effectiveness analyses, Integration of digital monitoring technologies and Quality-of life and patient-reported outcome measures.

❖ Advancements in precision medicine and digital health integration are expected to enhance therapeutic optimization in diabetes care.

REFERENCES

1. ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., ... & Gabbay, R. A. (2022). Introduction and methodology: standards of care in diabetes—2023. Diabetes care, 46(Suppl 1), S1.
2. Abousaber, I., Abdallah, H. F., & El-Ghaish, H. (2025). Robust predictive framework for diabetes classification using optimized machine learning on imbalanced datasets. Frontiers in Artificial Intelligence, 7, 1499530.
3. Care, D. (2023). Standards of care in diabetes—2023. Diabetes care, 46, S1-S267.
4. Ibrahim, N. A. B. (2023). An introduction to diabetes. Frontiers in Health Informatics, 12, 129.
5. Phillip, M., Bergenstal, R. M., Close, K. L., Danne, T., Garg, S. K., Heinemann, L., ... & Battelino, T. (2021). The digital/virtual diabetes clinic: the future is now—recommendations from an international panel on diabetes digital technology's introduction. Diabetes technology & therapeutics, 23(2), 146-154.
6. American Diabetes Association. (2022). Introduction: standards of medical care in diabetes—2022. Diabetes care, 45(Supplement_1), S1-S2.
7. Stanton, R. C. (2014). Frontiers in diabetic kidney disease: introduction. American Journal of Kidney Diseases, 63(2), S1-S2.
8. Umapathysivam, M. M., Gunton, J., Stranks, S. N., & Jesudason, D. (2024). Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care, 47(1), 140-143.
9. Templer, S., Abdo, S., & Wong, T. (2024). Preventing diabetes complications. Internal Medicine Journal, 54(8), 1264-1274.
10. Hossain, M. J., Al-Mamun, M., & Islam, M. R. (2024). Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Science Reports, 7(3), e2004.
11. Butt, M. D., Ong, S. C., Rafiq, A., Kalam, M. N., Sajjad, A., Abdullah, M., ... & Babar, Z. U. D. (2024). A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries. Journal of pharmaceutical policy and practice, 17(1), 2322107.

12. Wang, S., Chen, Y., Cui, Z., Lin, L., & Zong, Y. (2024). Diabetes risk analysis based on machine learning LASSO regression model. Journal of Theory and Practice of Engineering Science, 4(01), 58-64.
13. Asmi, A. S., & Saputra, M. K. F. (2024). Impact of home care counseling on the quality of life of people with diabetes militus. Jurnal Edukasi Ilmiah Kesehatan, 2(2), 49-55.
14. Abousaber, I., Abdallah, H. F., & El-Ghaish, H. (2025). Robust predictive framework for diabetes classification using optimized machine learning on imbalanced datasets. Frontiers in Artificial Intelligence, 7, 1499530.
15. Geurten, R. J., Struijs, J. N., Bilo, H. J., Ruwaard, D., & Elissen, A. M. (2024). Disentangling population health management initiatives in diabetes care: A scoping review. International Journal of Integrated Care, 24(1), 3.
16. Fève, B., & Scheen, A. J. (2022). When therapeutic drugs lead to diabetes. Diabetologia, 65(5), 751-762
17. Zhao, R., Lu, Z., Yang, J., Zhang, L., Li, Y., & Zhang, X. (2020). Drug delivery system in the treatment of diabetes mellitus. Frontiers in bioengineering and biotechnology, 8, 880.
18. Mai, Y., Meng, L., Deng, G., & Qin, Y. (2024). The Role of Type 2 Diabetes Mellitus Related Risk Factors and Drugs in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 159-171.
19. Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021). Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. Pharmaceuticals, 14(8), 806.
20. Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020). Type 2 diabetes mellitus: a review of multi-target drugs. Molecules, 25(8), 1987.
21. Hartuti, S., Nasution, A., & Syafril, S. (2021). The effect of drug-related problems on blood glucose level in the treatment of patients with type 2 diabetes mellitus. Open Access Macedonian Journal of Medical Sciences, 7(11), 1798.
22. . Zhuang, Z., & Bo, Y. (2025). Self-management and role of nurses of diabetic patients: a critical narrative literature review during COVID-19 pandemic. Frontiers in Medicine, 12, 1626447.
23. Bhanushali, P. (2024). Physical Therapy in Diabetic Patients Infected With Covid-19 Acute Post-Acute Recovery. Archives of Physical Medicine and Rehabilitation, 105(4), e147.

24. Shoji, M., Teramoto, N., Ishikawa, T., Hayashi, A., Matsumoto, A., Ochiai, H., ... & Koshizaka, M. (2024). Hypoalbuminemia on admission in diabetic patients correlates with severity of illness in COVID-19: A retrospective clinical study and literature review. Endocrine and Metabolic Science, 16, 100196.
25. Elian, V., Popovici, V., Karampelas, O., Pircalabioru, G. G., Radulian, G., & Musat, M. (2024). Risks and benefits of SGLT-2 inhibitors for type 1 diabetes patients using automated insulin delivery systems—a literature review. International Journal of Molecular Sciences, 25(4), 1972.
26. Cangelosi, G., Mancin, S., Pantanetti, P., Nguyen, C. T. T., Morales Palomares, S., Biondini, F., ... & Petrelli, F. (2024). Lifestyle Medicine Case Manager Nurses for Type Two Diabetes Patients: An Overview of a Job Description Framework—A Narrative Review. Diabetology, 5(4), 375-388.
27. Lombardi, S., Bocchi, L., & Francia, P. (2024). Photoplethysmography and artificial intelligence for blood glucose level estimation in diabetic patients: A scoping review. IEEE Access.